Lantheus Holdings (NASDAQ: LNTH) released first-quarter 2026 results, surpassing revenue forecasts with strong demand for prostate cancer diagnostics. Total net product sales reached $377.3 million, exceeding expectations of $354.87 million. Adjusted earnings per share hit $1.46, up from the anticipated $1.23, driven by an 18.7% increase in average list price to $1.46.
Financial Highlights
Shares climbed 5.95% to $90.01 following the announcement. Despite a 1.2% year-over-year revenue rise, the quarter showcased robust growth in precision oncology and radiopharmaceutical segments. GAAP diluted EPS stood at $1.23, while portfolio analysis highlights momentum in key areas.
Product Performance Breakdown
PYLARIFY, a leading PSMA PET agent for prostate imaging, generated $240.9 million in net sales, down 6.5% year-over-year but reflecting sustained market penetration. PYLARIFY accounted for 64% of revenue, underscoring its dominance. Panoramyc showed 5.8% average growth.
NeuraCeq, targeting amyloid PET for Alzheimer’s, posted $35.4 million in sales with 14.3% sequential growth in Q4 2025, positioning it as the fastest-growing beta-amyloid PET diagnostic. Officials note its role in assessing Alzheimer’s changes and brain metabolism.
DEFINITY, the top ultrasound contrast agent, delivered $84.6 million, up 6.8% year-over-year, justifying 80% of commercial demand.
SPECT sales totaled $25.2 million, down from prior peaks, but overall radiopharmaceutical transitions bolster the company’s foundation.
CEO Commentary
CEO Mary Anne Heino stated that overall growth provides a solid base for commercial momentum, emphasizing strategic factors in diagnostics.
Pipeline and Growth Drivers
Lantheus advances its radiopharmaceutical expansion. PYLARIFY TruVu received FDA approval on March 6, 2026, described as the next major step in PSMA PET portfolios. It offers unified diagnostics, larger batch production, corporate synergies, and entry into PMF networks.
HCPCS code applications support transitional pass-through payments with partners. Full conversion from PYLARIFY to TruVu occurs in Q2 2026, ensuring seamless operations without mid-quarter disruptions.
OCTEVY, a PSMA PET for imaging, faces FDA review with PDUFA extended to June 29, 2026. PNT2003 gained orphan status on March 2, 2026, as the first approved alternative to Lutetium Lu 177 Dotatate for GEP-NET cancers, with no major approvals until late June.
Pipeline Breadth
The pipeline spans 17 programs covering solid tumors, neuroendocrine cancers, cardiac applications, and neurological disorders. Key late-stage efforts include LNTH-2501/EVG001 and Lu-177 therapies for neuroendocrine indications.
Guidance and Outlook
Q1 GAAP EPS rose 76.5% to $1.80 year-over-year, incorporating $59.3 million from SPECT margins and $14.9 million from milestone impacts. Full-year adjusted EPS guidance is $5.00-$5.25, with revenue of $1.4-$1.45 billion.
Operating margins improved to 32.8% from 28.3%, fueled by largest customer expansions, new accounts, and pipeline leverage. Gross margin hit 67.0%, stable amid investments signaling real performance.
Analysts maintain 2026 as a year of operational execution and precision guidance, positioning for 2027 revenue acceleration. Risks include PSMA market dynamics and competition, but transitions like TruVu mitigate concerns.
Despite softer-than-expected PSMA growth and PYLARIFY’s 6.5% decline, strategic expansions in Alzheimer’s and oncology sustain long-term leadership.
